AbbVie chases its next golden goose in a post-Humira future with new ulcerative colitis data for Rinvoq
Still bathing in the afterglow of its big-money acquisition of Allergan, AbbVie faces the dark cloud of a post-Humira future — and the deadline is approaching fast. Key to AbbVie’s plan are two immunology launches with aggressive clinical dreams; one of those, JAK inhibitor Rinvoq, is now one step closer to another Humira-matching approval.
AbbVie’s Rinvoq (upadacitinib) bested placebo in helping ulcerative colitis patients achieve clinical remission at the eight-week mark and significantly reduced key symptomatic biomarkers, including gastrointestinal inflammation, according to data from the Phase III U-Achieve study unveiled Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.